Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?
作者信息
Tuttle R Michael, Haugen Bryan, Perrier Nancy D
机构信息
1 Memorial Sloan Kettering Cancer Center , New York, New York.
2 University of Colorado School of Medicine , Aurora, Colorado.
出版信息
Thyroid. 2017 Jun;27(6):751-756. doi: 10.1089/thy.2017.0102. Epub 2017 May 19.
Abstract
摘要
相似文献
1
Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?美国癌症联合委员会/肿瘤-淋巴结-转移分期系统（第八版）对分化型和间变性甲状腺癌的更新：有哪些变化及原因？
Thyroid. 2017 Jun;27(6):751-756. doi: 10.1089/thy.2017.0102. Epub 2017 May 19.
2
Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.分化型和间变性甲状腺癌：美国癌症联合委员会第八版癌症分期手册的重大变化。
CA Cancer J Clin. 2018 Jan;68(1):55-63. doi: 10.3322/caac.21439. Epub 2017 Nov 1.
3
Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging.间变性甲状腺癌：WHO 分类、临床病理特征和分期的更新。
Histol Histopathol. 2021 Mar;36(3):239-248. doi: 10.14670/HH-18-277. Epub 2020 Nov 10.
4
Anaplastic thyroid carcinoma.间变性甲状腺癌。
Semin Diagn Pathol. 2020 Sep;37(5):248-256. doi: 10.1053/j.semdp.2020.06.005. Epub 2020 Jun 24.
5
Commentary on the study of Walczyk et al. Poorly differentiated thyroid cancer in the context of the revised 2015 American Thyroid Association Guidelines and the Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System (eighth edition).关于瓦尔奇克等人研究的评论。2015年修订的美国甲状腺协会指南及更新的美国癌症联合委员会/肿瘤-淋巴结-转移分期系统（第八版）背景下的低分化甲状腺癌。
Clin Endocrinol (Oxf). 2019 Aug;91(2):245-246. doi: 10.1111/cen.14010. Epub 2019 May 24.
6
Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging.甲状腺分化良好型癌的甲状腺外侵犯的组织病理学评估中的观察者间变异性支持美国癌症联合委员会第八版肿瘤分期标准的新准则。
Thyroid. 2019 May;29(5):619-624. doi: 10.1089/thy.2018.0286. Epub 2019 Apr 27.
7
Fatal outcome of an anaplastic thyroid tumour.间变性甲状腺肿瘤的致命结局。
BMJ Case Rep. 2017 Oct 25;2017:bcr-2017-221672. doi: 10.1136/bcr-2017-221672.
8
Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma.第八版 AJCC TNM 分类对分化型甲状腺癌的预后价值。
Oral Oncol. 2017 Aug;71:81-86. doi: 10.1016/j.oraloncology.2017.06.004. Epub 2017 Jun 10.
9
Age Influences the Prognosis of Anaplastic Thyroid Cancer Patients.年龄影响间变性甲状腺癌患者的预后。
Front Endocrinol (Lausanne). 2021 Jul 27;12:704596. doi: 10.3389/fendo.2021.704596. eCollection 2021.
10
[A case of anaplastic transformation of thyroid carcinoma in the cervical lymph node metastasis].[1例甲状腺癌颈部淋巴结转移灶发生间变转化的病例]
Gan No Rinsho. 1985 Mar;31(3):318-22.
引用本文的文献
1
Development of a new TNM staging system for poorly differentiated thyroid carcinoma: a multicenter cohort study.一种用于低分化甲状腺癌的新TNM分期系统的开发：一项多中心队列研究。
Front Endocrinol (Lausanne). 2025 Aug 19;16:1586542. doi: 10.3389/fendo.2025.1586542. eCollection 2025.
2
Ultrasound features and thyroid function of patients with papillary thyroid carcinoma for predicting metastatic cervical lymph nodes with atypical ultrasound features.具有非典型超声特征的甲状腺乳头状癌患者的超声特征及甲状腺功能对预测颈部转移性淋巴结的作用
Front Oncol. 2025 Aug 8;15:1628205. doi: 10.3389/fonc.2025.1628205. eCollection 2025.
3
Differentiating oncocytic carcinoma from oncocytic adenoma: a comprehensive evaluation of preoperative characteristics and diagnostic approaches in a retrospective cohort study.鉴别嗜酸细胞癌与嗜酸细胞腺瘤：一项回顾性队列研究中术前特征及诊断方法的综合评估
Ann Surg Treat Res. 2025 Aug;109(2):105-112. doi: 10.4174/astr.2025.109.2.105. Epub 2025 Jul 30.
4
Predictive factors for failure in patients with N1b papillary thyroid carcinoma.N1b 型甲状腺乳头状癌患者治疗失败的预测因素。
World J Surg Oncol. 2025 Jul 31;23(1):307. doi: 10.1186/s12957-025-03694-5.
5
Structure-based molecular screening and dynamic simulation of phytocompounds targeting VEGFR-2: a novel therapeutic approach for papillary thyroid carcinoma.基于结构的针对血管内皮生长因子受体-2的植物化合物分子筛选及动力学模拟：一种甲状腺乳头状癌的新型治疗方法
Front Pharmacol. 2025 Jun 9;16:1583329. doi: 10.3389/fphar.2025.1583329. eCollection 2025.
6
Use and utility of endocrine multidisciplinary tumour board: an appraisal from a tertiary centre.内分泌多学科肿瘤病例讨论会的应用与效用：来自一家三级中心的评估
Front Endocrinol (Lausanne). 2025 May 27;16:1513893. doi: 10.3389/fendo.2025.1513893. eCollection 2025.
7
Associations between pathological features and radioactive iodine-refractory recurrent papillary thyroid carcinoma: with mutation analysis using recurrent samples.病理特征与放射性碘难治性复发性乳头状甲状腺癌之间的关联：基于复发性样本的突变分析
BMC Endocr Disord. 2025 May 20;25(1):134. doi: 10.1186/s12902-025-01954-9.
8
Prognostic factors for progression free survival in patients with medullary thyroid cancer: a multicenter cohort study.甲状腺髓样癌患者无进展生存期的预后因素：一项多中心队列研究。
Updates Surg. 2025 May 20. doi: 10.1007/s13304-025-02193-2.
9
A Challenging Diagnosis of Papillary Thyroid Carcinoma Arising From Malignant Struma Ovarii.源于恶性卵巢甲状腺肿的乳头状甲状腺癌的疑难诊断
Cureus. 2025 Apr 17;17(4):e82465. doi: 10.7759/cureus.82465. eCollection 2025 Apr.
10
Positive preoperative circulating tumor cells level associated with lymph node metastasis in papillary thyroid carcinoma patients with capsular invasion.术前循环肿瘤细胞水平呈阳性与有包膜侵犯的乳头状甲状腺癌患者的淋巴结转移相关。
World J Surg Oncol. 2025 May 14;23(1):190. doi: 10.1186/s12957-025-03842-x.
本文引用的文献
1
Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems.探讨乳头状甲状腺癌患者年龄与癌症特异性生存率之间的关系：重新思考当前的分期系统。
J Clin Oncol. 2016 Dec 20;34(36):4415-4420. doi: 10.1200/JCO.2016.68.9372. Epub 2016 Oct 28.
2
An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer.一项关于将55岁作为AJCC/UICC高分化甲状腺癌分期系统中风险分层临界值的国际多机构验证研究。
Thyroid. 2016 Mar;26(3):373-80. doi: 10.1089/thy.2015.0315. Epub 2016 Feb 25.
3
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南：美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
4
Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?分化型甲状腺癌的生存：年龄与之有何关系？
Thyroid. 2015 Oct;25(10):1106-14. doi: 10.1089/thy.2015.0104. Epub 2015 Aug 12.
5
Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer.对于年龄小于 45 岁的甲状腺乳头状癌患者，淋巴结转移的存在和数量与生存受损有关。
J Clin Oncol. 2015 Jul 20;33(21):2370-5. doi: 10.1200/JCO.2014.59.8391. Epub 2015 Jun 15.
6
Update on differentiated thyroid cancer staging.分化型甲状腺癌分期的最新进展。
Endocrinol Metab Clin North Am. 2014 Jun;43(2):401-21. doi: 10.1016/j.ecl.2014.02.010.
7
Prognostic nomograms to predict oncological outcome of thyroid cancers.预测甲状腺癌肿瘤学结局的预后列线图。
J Clin Endocrinol Metab. 2013 Dec;98(12):4768-75. doi: 10.1210/jc.2013-2318. Epub 2013 Oct 23.
8
Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients.分化型甲状腺癌患者的预期寿命在诊断时存在广泛局部肿瘤侵犯、侧方淋巴结或远处转移（≥45 岁），以及所有其他 DTC 患者正常的情况下会降低。
J Clin Endocrinol Metab. 2013 Jan;98(1):172-80. doi: 10.1210/jc.2012-2458. Epub 2012 Nov 12.
9
Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.预测甲状腺乳头状癌的预后：在1940年至1989年间于一家机构接受手术治疗的1779例患者队列中开发一种可靠的预后评分系统。
Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8.
Zotero 插件